Navigation Links
Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
Date:2/2/2009

FRAZER, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the company will exercise its option to license worldwide rights to Lupuzor(TM), an investigational medication for the treatment of Systemic Lupus Erythematosus, based on the promising interim results of the ImmuPharma Phase IIb study. Cephalon will assume all expenses for Phase III studies, regulatory filings and subsequent commercialization of the product.

ImmuPharma PLC received a $15 million upfront fee at the initiation of the deal last year. In exercising its option, Cephalon will pay ImmuPharma a one-time license fee of $30 million. ImmuPharma could receive future cash milestone payments upon the achievement of certain regulatory and sales milestones, as well as royalties on commercial sales of Lupuzor. The various cash milestone payments (including the option and license fees) may total up to approximately $500 million.

"We are pleased that this Phase IIb study shows a favorable efficacy and safety profile for Lupuzor," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon. "We will initiate plans to implement pivotal Phase III clinical trials this year."

"These study results are encouraging and bring us one step closer to providing the first specific medication for the treatment of lupus to patients living with this chronic, potentially life-threatening disease," said Frank Baldino, Jr., Ph.D., chairman and CEO of Cephalon. "Lupuzor recently received a notice of allowance for its novel composition of matter patent, which will support our development of the product. If our efforts are successful, this product and our recent deal with Ception Therapeutics will allow us to build a business unit focused on i
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis is ... reached with Switzerland -based Kenta ... human monoclonal antibody (mAb) products, and technologies. This ... products for treatment of infections by common pathogens ... aureus , Pseudomonas aeruginosa , Acinetobacter ...
(Date:5/17/2013)... Toronto, Canada (PRWEB) May 17, 2013 ... to understanding complex biological systems that can help predict ... Keynote speaker Dr. Sergey Stepaniants, Head of Computational Biology ... of computational biology tools to ensure high-quality genomics when ... tools can be applied to complex data sets to ...
(Date:5/17/2013)... IAC Industries wants to share with you the success ... set up and furnish a research lab knowing that the ... year’s time. How does a company make choices in lab ... is efficient and cost-effective? , The solution was the ... planners at DisperSol determined that the concept of modular lab ...
(Date:5/16/2013)... Tampa, FL (PRWEB) May 16, 2013 ... has named Barbara A. Myers, CAE, to the ... Development. In her new role, Myers will be ... event development and production strategies, advancing the Society’s ... development processes and continuing to refine organizational, membership ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
... JUPITER, Fla., May 12, 2011 Stem Cell Assurance, ... General Form for Registration of Securities on Form 10 pursuant ...  The Form 10 includes audited financial statements as of December ...  Based upon this filing, effective July 11, 2011, the Company ...
... 2011 The Maryland Academy of Sciences and the ... its Annual Awards which recognize the accomplishments of young ... Appelbaum, Associate Professor of Physics at the University of ... and Dr. Ganesh Sriram, Assistant Professor in the Department ...
... a private clinical-stage biotherapeutics company focused on the development ... today announced that key data from its Phase 2 ... with data from other JX-594 clinical trials, will be ... Therapy (ASGCT) Annual Meeting taking place May 18-21, 2011, ...
Cached Biology Technology:2011 Outstanding Young Scientist and Engineer Named; Baltimore City High School Students Awarded Glass Scholarships 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 3Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 4
(Date:5/16/2013)... at MIT may someday eliminate the need for ... their blood-sugar levels and inject themselves with insulin. ... levels in the body and respond by secreting ... function of pancreatic islet cells, which are destroyed ... type of system could ensure that blood-sugar levels ...
(Date:5/16/2013)... discovered an ancient extinct creature with ,scissor hand-like, claws ... of his favourite movie star. , The 505 ... (pronounced Koo-ten-ee-che-la depp-eye), which is a distant ancestor of ... Depp for his starring role as Edward Scissorhands - ... unfinished creation, who has scissors for hands. , ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... academics from the University of Sheffield has shown for the ... skills and nutritional status of older people with dementia. ... Journal of Geriatric Psychiatry and funded by the National ... to assess the eating patterns of dementia patients in Taiwan. ...
... soils could play a part in the formation of the ... coast beaches in summer., A QUT team of scientists is ... iron-rich soil its red colour, reaches water to potentially contribute ... smell, but also make our eyes sting, cause fich kills ...
... in the body,s regulation of iron levels should provide a ... well as rare, potentially deadly iron overload, researchers said. ... of Blood that the protein neogenin, a receptor ... body,s interwoven regulatory process for iron. The receptor, located on ...
Cached Biology News:New method improves eating skills of dementia patients 2Is iron from soil a factor in algal blooms? 2Potential new target for drugs to treat iron deficiency and overload discovered 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... contains 5 ml of DETACHaBEAD 19 ... Dynabeads CD19 (Pan B). B ... B) and released with DETACHaBEAD CD19 ... are suitable for applications such as ...
Request Info...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Biology Products: